| 康晓迪,许艳丽,白玉青,刘 军,孙芳俐,易 为.替诺福韦治疗慢性乙型肝炎的疗效及对血清HA、LN、IV-C、PC-III的影响[J].现代生物医学进展英文版,2021,(16):3059-3063. |
| 替诺福韦治疗慢性乙型肝炎的疗效及对血清HA、LN、IV-C、PC-III的影响 |
| Efficacy of Tenofovir in the Treatment of Chronic Hepatitis B and Its Effect on Serum HA, LN, IV-C and PC-III |
| Received:February 04, 2021 Revised:February 27, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.16.012 |
| 中文关键词: 替诺福韦 慢性乙型肝炎 透明质酸 层粘连蛋白 IV型胶原蛋白 Ⅲ型前胶原肽 |
| 英文关键词: Tenofovir Chronic hepatitis b Hyaluronic acid Laminin Type IV collagen Before Ⅲ type collagen peptide |
| 基金项目:北京市医院管理局2017年度（第三期）"青苗"计划（QML20171803） |
|
| Hits: 937 |
| Download times: 501 |
| 中文摘要: |
| 摘要 目的：探讨替诺福韦治疗慢性乙型肝炎的疗效及对血清透明质酸（HA）、层粘连蛋白（LN）、IV型胶原蛋白（IV-C）、Ⅲ型前胶原肽（PC-III）的影响。方法：选择2018年1月到2020年1月在我院进行治疗的101例慢性乙型肝炎患者进行研究，采用随机数表法分为试验组（n=51）和对照组（n=50）。对照组给予恩替卡韦治疗，试验组给予替诺福韦治疗。比较两组临床疗效、血清HA、LN、IV-C、PC-III、HBV-DNA、乙肝表面抗原（HBsAg）、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）水平变化情况及药物不良反应发生情况。结果：治疗后，两组总有效率比较差异显著（P<0.05）；与治疗前比较，试验组和对照组血清HA、LN、IV-C、PC-III水平检验结果比较无显著差异；治疗后，试验组和对照组血清HA、LN、IV-C、PC-III水平均随着时间的推移而降低，且试验组低低于对照组，差异显著（P<0.05）；与治疗前比较，试验组和对照组血清HBV-DNA、HBsAg水平检验结果比较无显著差异；治疗后，试验组和对照组血清HBV-DNA、HBsAg水平均随着时间的推移而下降，且试验组低于对照组，差异显著（P<0.05）；与治疗前比较，试验组和对照组血清ALT、AST水平检验结果比较无显著差异；治疗后，试验组和对照组血清ALT、AST水平均随着时间的推移而降低，且试验组低低于对照组，差异显著（P<0.05）；两组不良反应总发生率分别为7.84%、10.00%（P>0.05）。结论：慢性乙型肝炎采用替诺福韦效果显著，可能与其可有效改善血清THA、LN、IV-C、PC-III水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study Efficacy of tenofovir in the treatment of chronic hepatitis B and its effect on serum Hyaluronic acid (HA), laminin (LN), type IV collagen (IV - C), a former Ⅲ type collagen peptide (PC - III). Methods: 101 patients with chronic hepatitis B who were treated in our hospital from January 2018 to January 2020 were selected for this study. They were divided into experimental group (n=51) and control group (n=50) by random number table method. The control group received entecavir treatment and the experimental group received tenofovir treatment. Clinical efficacy, changes in serum HA, LN, IV-C, PC-III, HBV-DNA, hepatitis B surface antigen (HBsAg), alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels and the incidence of adverse drug reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different (P<0.05). Compared with before treatment, there were no significant differences in serum HA, LN, IV-C and PC-III levels between the experimental group and the control group. After treatment, the serum levels of HA, LN, IV-C and PC-III in experimental group and control group decreased with time, and the levels in experimental group were lower than those in control group, the differences were significant (P<0.05). Compared with before treatment, serum HBV-DNA and HBsAg levels of the experimental group and the control group were not significantly different. After treatment, the levels of serum HBV-DNA and HBsAg in experimental group and control group decreased with the passage of time, and the difference was significant (P<0.05). Compared with before treatment, there was no significant difference in serum ALT and AST levels between the experimental group and the control group. After treatment, the serum levels of ALT and AST in experimental group and control group decreased with the passage of time, and the levels in experimental group were lower than those in control group, the difference was significant (P<0.05). The total incidence of ADR in the two groups was 7.84% and 10.00% (P>0.05), respectively. Conclusion: The effect of tenofovir on chronic hepatitis B may be related to its effective improvement of serum THA, LN, IV-C and PC-III levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
